US Markets

FDA delays approval of Spectrum Pharma's drug due to COVID-19

Spectrum Pharmaceuticals said on Monday the U.S. Food and Drug Administration has deferred approval of its experimental drug for treating chemotherapy induced loss of white blood cells in cancer patients, due to COVID-19 related travel restrictions.

Oct 26 (Reuters) - Spectrum Pharmaceuticals SPPI.O said on Monday the U.S. Food and Drug Administration has deferred approval of its experimental drug for treating chemotherapy induced loss of white blood cells in cancer patients, due to COVID-19 related travel restrictions.

The decision was taken as the U.S. health agency was unable to conduct an inspection of company's South Korea-based manufacturing plant, required before drug approval, due to restrictions on travel related to the COVID-19 pandemic.

(Reporting By Mrinalika Roy in Bengaluru; Editing by Shailesh Kuber)

((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SPPI

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More